NCT03254277View on ClinicalTrials.gov

3BNC117-LS First-in-Human Phase 1 Study

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 13, 2017

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Human Immunodeficiency Virus
Interventions
DRUG

3BNC117-LS

Intravenous infusion of 3BNC117-LS

DRUG

Placebo

Placebo

Trial Locations (1)

10065

The Rockefeller University, New York

All Listed Sponsors
lead

Rockefeller University

OTHER

NCT03254277 - 3BNC117-LS First-in-Human Phase 1 Study | Biotech Hunter | Biotech Hunter